Hope on the horizon: new drug trial aims to slow rare brain disease PSP
NCT ID NCT07264283
First seen Jan 05, 2026 · Last updated May 17, 2026 · Updated 18 times
Summary
This Phase 2 trial tests whether the drug LM11A-31 can slow the progression of Progressive Supranuclear Palsy (PSP), a rare brain disease that affects movement and thinking. About 147 people with early-stage PSP will receive the drug or a placebo. The study measures changes in symptoms over time using a specialized rating scale.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSP - PROGRESSIVE SUPRANUCLEAR PALSY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.